PharmaTech Recalls Product Due to Contamination Risk
The company is voluntarily recalling liquid products due to possible Burkholderia cepacia contamination.
PharmaTech, LLC (Davie, FL) announced on August 8, 2016 that the company was voluntarily recalling all of its liquid products manufactured from Oct. 20, 2015–July 15, 2016. The recall is due to the potential risk for Burkholderia cepacia (B. cepacia) contamination in the recalled products.
Patients with compromised immune systems and patients with chronic lung conditions could be at risk of infection if they use products contaminated with B. cepacia, according to the company. The company, however, states in a press release that it has not received any complaints of contamination associated with the recalled lots. A list of recalled lots can be found here.
PharmaTech is notifying customers and distributors of the recall and is stating that consumers, pharmacies, and healthcare facilities should stop using the products immediately. Adverse events can be reported to FDA at www.fda.gov/medwatch/report.htm.
Source: FDA
Editor's Note: Pharmaceutical Technology magazine is not affiliated with the recall. All inquiries should be directed to PharmaTech, LLC.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
